Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Dexamethasone 307Bortezomib 161Lenalidomide 130pomalidomide 112daratumumab 94carfilzomib 69Calcium Dobesilate 41Cyclophosphamide 40belantamab mafodotin 31elotuzumab 30fludarabine 27ixazomib 23isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Myeloma × milatuzumab × Clear all
NCT01663766 2021-08-19

Phase I Study of Milatuzumab for Graft Versus Host Disease

Gilead Sciences

Phase 1 Terminated
12 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00421525 2021-08-16

Phase I/II Study of hLL1 in Multiple Myeloma

Gilead Sciences

Phase 1/2 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡